Neuronetics (FRA:NRC) Debt-to-Revenue : 0.90 (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Neuronetics Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Neuronetics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.78 Mil. Neuronetics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €56.69 Mil. Neuronetics's annualized Revenue for the quarter that ended in Mar. 2024 was €64.10 Mil. Neuronetics's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.90.

Neuronetics Debt-to-Revenue Historical Data

The historical data trend for Neuronetics's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuronetics Debt-to-Revenue Chart

Neuronetics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

0.55

0.78

0.72

0.61

0.88

Neuronetics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Revenue	Get a 7-Day Free Trial															0.65	0.57	0.56	0.77	0.90

Competitive Comparison of Neuronetics's Debt-to-Revenue

For the Diagnostics & Research subindustry, Neuronetics's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neuronetics's Debt-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Neuronetics's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Neuronetics's Debt-to-Revenue falls into.

Neuronetics Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Neuronetics's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.775	+	56.514)	/	65.426
	=	0.88

Neuronetics's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.783	+	56.693)	/	64.096
	=	0.90

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.

Neuronetics Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Neuronetics's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Neuronetics (FRA:NRC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Neuronetics Inc (FRA:NRC) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

STIM:USA NRC:Germany

Address

3222 Phoenixville Pike, Malvern, PA, USA, 19355

Website

https://www.neurostar.com

Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.